Literature DB >> 29954943

A genetic model to study O-GlcNAc cycling in immortalized mouse embryonic fibroblasts.

Melissa M St Amand1,2, Michelle R Bond2, Julia Riedy1, Marcella Comly2, Joseph Shiloach1, John A Hanover3.   

Abstract

O-GlcNAcylation is an abundant posttranslational protein modification in which the monosaccharide O-GlcNAc is added to Ser/Thr residues by O-GlcNAc transferase and removed by O-GlcNAcase. Analyses of O-GlcNAc-mediated signaling and metabolic phenomena are complicated by factors including unsatisfactory inhibitors and loss-of-function cell lines lacking identical genetic backgrounds. In this work, we generated immortalized WT, Oga knockout, and Ogt floxed allele (Ogt floxed) mouse embryonic fibroblast (MEF) cell lines with similar genetic backgrounds. These lines will facilitate experiments and serve as a platform to study O-GlcNAc cycling in mammals. As a test paradigm, we used the immortalized MEF lines to investigate how changes in O-GlcNAcylation affected pathological phosphorylation of the tau protein. The activity of glycogen synthase kinase 3β (GSK3β), a kinase that phosphorylates tau, decreases when expressed in Oga knockout MEFs compared with WT cells. Phosphorylation at Thr231 in recombinant, tauopathy-associated tau with a proline-to-leucine mutation at position 301 (P301L) was altered when expressed in MEFs with altered O-GlcNAc cycling. In aggregate, our data support that O-GlcNAc cycling indirectly affects tau phosphorylation at Thr231, but tau phosphorylation was highly variable, even in genetically stable, immortalized MEF cells. The variable nature of tau phosphorylation observed here supports the need to use cells akin to those generated here with genetically defined lesions and similar backgrounds to study complex biological processes.

Entities:  

Keywords:  (O-GlcNAc); O-GlcNAc transferase (OGT); O-GlcNAcylation; Tau protein (Tau); fibroblast; glycogen synthase kinase 3 (GSK3); protein phosphorylation; tauopathy

Mesh:

Substances:

Year:  2018        PMID: 29954943      PMCID: PMC6120200          DOI: 10.1074/jbc.RA118.004059

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  39 in total

1.  Dynamic O-GlcNAc modification of nucleocytoplasmic proteins in response to stress. A survival response of mammalian cells.

Authors:  Natasha E Zachara; Niall O'Donnell; Win D Cheung; Jessica J Mercer; Jamey D Marth; Gerald W Hart
Journal:  J Biol Chem       Date:  2004-05-11       Impact factor: 5.157

2.  Beta-N-acetylglucosamine (O-GlcNAc) is part of the histone code.

Authors:  Kaoru Sakabe; Zihao Wang; Gerald W Hart
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-02       Impact factor: 11.205

3.  β-N-Acetylglucosamine (O-GlcNAc) is a novel regulator of mitosis-specific phosphorylations on histone H3.

Authors:  Jerry J Fong; Brenda L Nguyen; Robert Bridger; Estela E Medrano; Lance Wells; Shujuan Pan; Richard N Sifers
Journal:  J Biol Chem       Date:  2012-02-27       Impact factor: 5.157

4.  The O-GlcNAc transferase gene resides on the X chromosome and is essential for embryonic stem cell viability and mouse ontogeny.

Authors:  R Shafi; S P Iyer; L G Ellies; N O'Donnell; K W Marek; D Chui; G W Hart; J D Marth
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

5.  A lipid-droplet-targeted O-GlcNAcase isoform is a key regulator of the proteasome.

Authors:  Chithra N Keembiyehetty; Anna Krzeslak; Dona C Love; John A Hanover
Journal:  J Cell Sci       Date:  2011-08-15       Impact factor: 5.285

6.  Human keratinocytes are efficiently immortalized by a Rho kinase inhibitor.

Authors:  Sandra Chapman; Xuefeng Liu; Craig Meyers; Richard Schlegel; Alison A McBride
Journal:  J Clin Invest       Date:  2010-07       Impact factor: 14.808

7.  c-Myc is glycosylated at threonine 58, a known phosphorylation site and a mutational hot spot in lymphomas.

Authors:  T Y Chou; G W Hart; C V Dang
Journal:  J Biol Chem       Date:  1995-08-11       Impact factor: 5.157

8.  Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain: Implication for Alzheimer's disease.

Authors:  Yanqiu Deng; Bin Li; Ying Liu; Khalid Iqbal; Inge Grundke-Iqbal; Cheng-Xin Gong
Journal:  Am J Pathol       Date:  2009-10-08       Impact factor: 4.307

9.  Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3beta (GSK3beta) plays a critical role in regulating tau's ability to bind and stabilize microtubules.

Authors:  Jae-Hyeon Cho; Gail V W Johnson
Journal:  J Neurochem       Date:  2004-01       Impact factor: 5.372

10.  Preparation, culture, and immortalization of mouse embryonic fibroblasts.

Authors:  Jianming Xu
Journal:  Curr Protoc Mol Biol       Date:  2005-05
View more
  5 in total

Review 1.  Critical observations that shaped our understanding of the function(s) of intracellular glycosylation (O-GlcNAc).

Authors:  Natasha E Zachara
Journal:  FEBS Lett       Date:  2018-11-24       Impact factor: 4.124

2.  Short O-GlcNAcase Is Targeted to the Mitochondria and Regulates Mitochondrial Reactive Oxygen Species Level.

Authors:  Patrick Pagesy; Abdelouhab Bouaboud; Zhihao Feng; Philippe Hulin; Tarik Issad
Journal:  Cells       Date:  2022-06-02       Impact factor: 7.666

Review 3.  Mapping the O-GlcNAc Modified Proteome: Applications for Health and Disease.

Authors:  Rajan A Burt; Ibtihal M Alghusen; Sophiya John Ephrame; Maria T Villar; Antonio Artigues; Chad Slawson
Journal:  Front Mol Biosci       Date:  2022-05-19

4.  Nutrient-Driven O-GlcNAcylation Controls DNA Damage Repair Signaling and Stem/Progenitor Cell Homeostasis.

Authors:  Hyun-Jin Na; Ilhan Akan; Lara K Abramowitz; John A Hanover
Journal:  Cell Rep       Date:  2020-05-12       Impact factor: 9.995

5.  Blocked O-GlcNAc cycling alters mitochondrial morphology, function, and mass.

Authors:  Elizabeth O Akinbiyi; Lara K Abramowitz; Brianna L Bauer; Maria S K Stoll; Charles L Hoppel; Chao-Pin Hsiao; John A Hanover; Jason A Mears
Journal:  Sci Rep       Date:  2021-11-11       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.